Press Release
Printer-Friendly
News |
AAIPharma chooses SAS’ clinical trials solution to support rapid growthCARY, NC (Sept. 10, 2007) – SAS, the leader in business intelligence, today announced that AAIPharma will help fuel its ongoing global expansion efforts by using SAS® Drug Development, SAS’ powerful data management, collaborative reporting and analysis solution for pharmaceutical, medical device and biotechnology firms. A leading contract research organization, AAIPharma will use SAS Drug Development to improve the efficiency of service delivery in clinical data management and biostatistics, as well as to integrate, harmonize and scale biostatistics services in a regulatory compliant environment. “SAS has a proven track record in supplying effective, easy-to-use software for the life sciences industry,” said Anne Wiles, AAIPharma Senior Vice President, Data Systems and Processes. “We’re looking to take advantage of SAS’ expertise and the great working relationship we have already forged to help accelerate and streamline the management and analysis of our clinical trials data.” AAIPharma is a rapidly expanding provider of contract research services to the pharmaceutical, biotech and medical device industries. This year alone, AAIPharma has strengthened its clinical development capabilities in Spain, Latin America, Hungary and South Africa; expanded its global Phase I capacity to more than 300 beds at facilities across Germany and the US; and bolstered its services to biotechnology clients in pharmaceutical development and sterile products manufacturing by investing more than US $2 million in its facilities in Charleston, SC, and Wilmington, NC. “Our mutual customers are looking for greater visibility into research progress and outcomes”, said Jason Burke, Worldwide Director of the SAS Health and Life Sciences Global Practice. “AAIPharma and SAS share a common vision for facilitating improvements in drug development through earlier, deeper and more frequent access to critical research information.” SAS Drug Development leverages the breakthrough capabilities of the SAS Enterprise Intelligence Platform to remove the obstacles in sharing data and applications across organizations and deliver the foresight and understanding required to succeed. Available as a standalone or hosted solution with access via a secure, thin client, SAS Drug Development provides data integration and analysis, allowing life sciences firms to analyze their clinical research for regulatory submission and explore new market opportunities, product line extensions and safety issues – all within a controlled and secure collaborative framework designed for life sciences research industries. SAS Drug Development has been designed to meet federal regulations such as 21 CFR Part 11, good industry practices and sound business practices. About AAIPharmaAAIPharma Inc. is a global provider of product development and support services to the pharmaceutical, biotechnology and medical device industries. From a single test through a range of integrated service offerings, we create value to an industry in search of productivity and innovation. For more information on the Company, please visit AAIPharma's website at www.aaipharma.com.
SAS is the leader in business intelligence and analytical software and services. Customers at 43,000 sites use SAS software to improve performance through insight from data, resulting in faster, more accurate business decisions; more profitable relationships with customers and suppliers; compliance with governmental regulations; research breakthroughs; and better products and processes. Only SAS offers leading data integration, storage, analytics and business intelligence applications within a comprehensive enterprise intelligence platform. Since 1976, SAS has been giving customers around the world
The Power to Know®
.
|
Editorial Contacts:
Visit the SAS Press Center for more information. |